Brief: Sinomab Bioscience Receives Ind Approval For SM17 By NMPA
11/09/2023 14:59
Sept 11 (Reuters) - SinoMab BioScience Ltd 3681.HK :
* IND APPROVAL FOR SM17 BY NMPA
* ON SEPT 8, IND FOR TREATMENT OF PATIENTS WITH ATOPIC
DERMATITIS
FOR CO'S THERAPEUTIC PRODUCT SM17 WAS APPROVED BY NMPA
Source text for Eikon: ID:nHKS1nCytC
Further company coverage: 3681.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sinomab Bioscience
See all newsBrief: Sinomab Bioscience Posts HY Loss Of RMB127.4 Million
Brief: Sinomab Bioscience Says Fang Liang Resigns As Executive Director
Brief: Sinomab Bioscience Announces Major Deal For Disposal Of Suzhou Property And Facility For RMB280 MLN
Brief: SinoMab Bioscience Appoints Fang Liang As Executive Director
Brief: Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience